An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors by Russell J. Schilder, Drew Rasco, Manish R. Sharma

Get full text

Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors by Dirk Schadendorf, Ignacio Melero, Robert L Ferris, William Sharfman, Satyendra Suryawanshi, Jaclyn Neely, Fabrice Barlesi, Dung T Le, Jason J Luke, Patrick A Ott, Tina Cascone, Nikhil I Khushalani, Abanti Sanyal, Scott Ely, Manish R Sharma, Deanne Lathers, James L Holloway, Rasika Suryawanshi, Neil H Segal

Get full text

Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies by Quchang Ouyang, Jordi Rodon, Yan Liang, Xinhong Wu, Qun Li, Lihua Song, Min Yan, Zhongsheng Tong, YunPeng Liu, Zev A. Wainberg, Ying Wang, Cuizhi Geng, Susanna V. Ulahannan, Guohua Yu, Manish R. Sharma, Xiang Wang, Judy S. Wang, Alexander Spira, Weihong Zhao, Rachel E. Sanborn, Ying Cheng, Xian Wang, Gesha Liu, Yaling Li, Junyou Ge, Elliot Chartash, Omobolaji O. Akala, Yongmei Yin

Get full text